Recombinant monoclonal antibody to CD22. Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).
Applications: IF, IP, Neut, FuncS, ELISA, FC, ICC, Activ, WB
Figure 1 Epratuzumab measured KD on Biacore.
Affinity of epratuzumab for CD22 ECD was determined by measuring binding of free epratuzumab to a Biacore column after competition with soluble CD22 ECD (A). B, kinetics of direct epratuzumab binding (0.8–200 nm) over a CD22 ECD surface, showing a very slow off rate. Cloned, Chinese hamster ovary-expressed, and purified CD22 ECD (as shown in panel C) on the blotted membrane with rabbit anti-CD22 was used for molecular characterization of epratuzumab binding.
Figure 2 Epratuzumab induces phosphorylation of CD22.
Daudi or Ramos cell lines were treated for 15 min at 37°C with a saturating dose of epratuzumab, epratuzumab and a cross-linker, or a B cell receptor activator, anti-IgM. Cells were lysed and CD22 was immunoprecipitated to examine the signaling potential of epratuzumab, using phosphotyrosine-specific antibody (top). To ensure equal CD22 loading, immunoblots were stripped and reprobed with a polyclonal rabbit anti-CD22 (bottom) (see "Materials and Methods").
Figure 3 FITC-epratuzumab direct internalization.
FITC-labeled epratuzumab was used to label Daudi tumor cells on ice for 30 min. Cells were subsequently washed and allowed to incubate for an additional 60 min at either 4°C (left) or 37°C (right). CD22 internalization is evident from capping and punctate staining of endocytic vesicles (arrows) visible in cells incubated at 37°C.
Figure 4 CD22 internalization as measured by flow cytometry using a noncompeting anti-CD22 antibody.
Daudi cells were incubated in the presence of 5 μg/ml epratuzumab (Emab) for 20 h at 37°C and analyzed by flow cytometry for CD22 internalization (A) as observed by an apparent lowering of cell surface CD22, measured with the FITC-S-HCL1 anti-CD22 monoclonal antibody. B, evidence that adding increasing epratuzumab concentrations together with FITC-labeled S-HCL1 did not result in lowering the signal observed with FITCH-SCI1 alone (solid blue trace). This confirms that these two anti-CD22 monoclonal antibodies recognize distinct and noncompeting epitopes on CD22 (FACS using the Daudi cell line). FSC-H, forward scatter; SSC-H, side scatter.
Figure 5 Quantification of CD22 receptor density after epratuzumab treatment.
Daudi lymphoma cells (106 cells/ml) were incubated with increasing concentrations of epratuzumab in RPMI supplemented with 10% FBS for 1 h at 37°C. Cells were then washed with cold PBS and immediately analyzed by FACS for CD22 receptor quantification as described. The resulting CD22 density as measured with QuantiBRITE beads and H-SCL1 PE labeled is shown as a percentage of total CD22 on untreated cells (100%). At 5 μg/ml, cells have reached the maximum level of internalization, which is 70% in this experiment.
Figure 6 Epratuzuma-induced CD22 internalization kinetics.
Daudi cells and tonsil-derived mononuclear cells were incubated with increasing incubation time in the presence of 25 μg/ml epratuzumab/ At the end of each time point, cells were immunostained with anti-CD22 H-SCL1-PE only (Daudi) or anti-CD19-FITC and anti-CD22-PE (tonsils) for receptor quantification, as described. At early time points, the Daudi cell line is more efficacious in receptor internalization. After prolonged treatment, however (>18 h), no internalization efficiency difference between cell lines and primary cells could be observed.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-CD22 ADCC Recombinant Antibody (Epratuzumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD22. Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).
|MOB-1248z-S(P)||Recombinant Anti-Human CD22 Antibody scFv Fragment||ELISA, WB, IF, FuncS||scFv|
|FAMAB-0046-YC-S(P)||Mouse Anti-CD22 Recombinant Antibody (clone m5/44); scFv Fragment||ELISA, Cyt||Mouse scFv|
|HPAB-N0324-YC-S(P)||Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-N0324-YC-S(P))||FuncS||Mouse scFv|
|HPAB-N0325-YC-S(P)||Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (HPAB-N0325-YC-S(P))||FuncS||Mouse scFv|
|HPAB-2052-FY-S(P)||Human Anti-CD22 Recombinant Antibody (clone B28); scFv Fragment||FC||Human scFv|
|TAB-899||Humanized Anti-CD22 Recombinant Antibody (clone Pinatuzumab)||FC, IP, ELISA, Neut, FuncS, IF, ICC||Humanized (from mouse) IgG1, κ|
|TAB-1725CL||Human Anti-CD22 Recombinant Antibody (TAB-1725CL)||Block, Cyt, ELISA, FuncS||Humanized IgG|
|TAB-1729CL||Human Anti-CD22 Recombinant Antibody (TAB-1729CL)||IF, FC||Humanized IgG|
|TAB-1725CL-S(P)||Human Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1725CL-S(P))||Block, Cyt, ELISA, FuncS||Humanized scFv|
|TAB-1729CL-S(P)||Human Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1729CL-S(P))||IF, FC||Humanized scFv|
|AGTO-G077E||Anti-CD22 immunotoxin RFB4 (IgG)-PE||Cytotoxicity assay, Function study|
|AGTO-G077D||Anti-CD22 immunotoxin RFB4 (IgG)-DT||Cytotoxicity assay, Function study|
|AGTO-G077G||Anti-CD22 immunotoxin RFB4 (IgG)-Gel||Cytotoxicity assay, Function study|
|AGTO-G077R||Anti-CD22 immunotoxin RFB4 (IgG)-RTA||Cytotoxicity assay, Function study|
|AGTO-G077S||Anti-CD22 immunotoxin RFB4 (IgG)-Sap||Cytotoxicity assay, Function study|
|TAB-0196CL||Anti-Human CD22 Recombinant Antibody (hLL2)||Inhib, Cyt, FC, WB|
|TAB-0197CL||Anti-Human CD22 Recombinant Antibody (hLL2-Cys)||ELISA, In vivo|
|TAB-1715CL||Anti-Human CD22 Recombinant Antibody (12C5)||Cyt, FuncS||Fully human antibody|
|TAB-1716CL||Anti-Human CD22 Recombinant Antibody (19A3)||Cyt, FuncS||Fully human antibody|
|TAB-1717CL||Anti-Human CD22 Recombinant Antibody (16F7)||Cyt, FuncS||Fully human antibody|
|TAB-1724CL||Human Anti-CD22 Recombinant Antibody (TAB-1724CL)||Inhib||Chimeric (mouse/human) IgG1, κ|
|TAB-1724CL-S(P)||Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-1724CL-S(P))||Inhib||Mouse scFv|
|TAB-001LC||Human Anti-CD22 Recombinant Antibody (TAB-001LC)||ELISA||Chimeric antibody (mouse/human)|
|TAB-001LC-S(P)||Mouse Anti-CD22 Recombinant Antibody; scFv Fragment (TAB-001LC-S(P))||ELISA||Mouse scFv|
|TAB-001LC-F(E)||Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-001LC-F(E))||ELISA||Chimeric antibody (mouse/human)|
|TAB-1714CL-F(E)||Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1714CL-F(E))||ELISA, WB||Mouse Fab|
|TAB-1723CL-F(E)||Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1723CL-F(E))||Inhib||Mouse Fab|
|TAB-1728CL-F(E)||Anti-Human CD22 Recombinant Antibody Fab Fragment (RFB4)||IF, FC|
|TAB-003LC||Mouse Anti-Human CD22 Recombinant Antibody||FC|
|TAB-004LC||Anti-Human CD22 Recombinant Antibody||FC|
|Gly-001LC||Recombinant Anti-Human CD22 Antibody (Fab glycosylation)||ELISA, FC||Mouse antibody|
|Gly-111LC||Recombinant Anti-Human CD22 Antibody (Fc glycosylation)||ELISA||Chimeric antibody (mouse/human)|
|NEUT-315CQ||Rat Anti-CD22 Recombinant Antibody (clone 2D6)||Block||Rat IgG1, κ|
|MOR-0545||Hi-Affi™ Rabbit Anti-CD22 Recombinant Antibody (clone DS545AB)||IP, WB||Rabbit IgG|
|HPAB-0195-LSX||Human Anti-CD22 Recombinant Antibody (HPAB-0195-LSX)||Apop, Cyt, FC, WB, Inhib, FuncS, IF, ELISA||Human IgG|
|HPAB-0196-LSX||Mouse Anti-CD22 Recombinant Antibody (HPAB-0196-LSX)||ELISA, FC, IP, RIA||Mouse IgG|
|HPAB-0197-LSX||Human Anti-CD22 Recombinant Antibody (HPAB-0197-LSX)||ELISA, FC, FuncS||Human IgG|
|HPAB-0198-LSX||Mouse Anti-CD22 Recombinant Antibody (HPAB-0198-LSX)||ELISA, WB, IF, FC, SPR||Mouse IgG|
|HPAB-0199-LSX||Human Anti-CD22 Recombinant Antibody (HPAB-0199-LSX)||ELISA, FC||Human IgG1|
|HPAB-0194-LSX-F(E)||Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0194-LSX-F(E))||ELISA||Mouse Fab|
|HPAB-0195-LSX-F(E)||Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0195-LSX-F(E))||ELISA||Human Fab|
|HPAB-0196-LSX-F(E)||Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0196-LSX-F(E))||ELISA||Mouse Fab|
|HPAB-0197-LSX-F(E)||Human Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0197-LSX-F(E))||ELISA||Human Fab|
|HPAB-0198-LSX-F(E)||Mouse Anti-CD22 Recombinant Antibody; Fab Fragment (HPAB-0198-LSX-F(E))||ELISA, FC||Mouse Fab|
|AFC-TAB-176||Afuco™ Anti-CD22 ADCC Recombinant Antibody (Epratuzumab), ADCC Enhanced||IF, IP, Neut, FuncS, ELISA, FC||ADCC enhanced antibody|
|AFC-TAB-198||Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced||ELISA, FC, IP, FuncS, IF, Neut||ADCC enhanced antibody|
Thare are currently no Customer reviews or questions for TAB-176. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.